News & Events
BIO EQUITY | San Sebastian, Spain | 12 – 14 May 2024
Our CEO Marco Timmers and CBO Sijme Zeilemaker will be attending BioEquity in San Sebastian, Spain on May 12-14. Marco and Sijme are welcoming opportunities to connect and give an update on our Series A financing and our approach for next-generation RNA therapeutics.
BIO INTERNATIONAL CONVENTION | San Diego, CA | 3 – 6 June 2024
Sapreme’s Chief Business Officer Sijme Zeilemaker will be attending BIO 2024, San Diego in the first week of June this year. If you would like to learn more about our pipeline of targeted RNA therapeutics and endosomal escape technology to improve your RNA therapeutics, feel free to reach out to us!
Press Releases
Bilthoven, July 20, 2023
Sapreme announced today the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors. Both bring a wealth of executive, business and clinical development expertise from large pharmaceutical and innovative biotech companies as Sapreme now builds upon preclinical proof of concept in several disease indications and delivery models. Read the full press release here.
October 7, 2021
Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.
About Sapreme:
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.
Contacts: Guy Hermans, CEO | +31 30 760 09 76 | hermans@sapreme-technologies.com
For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher | +49 89 238 877 30 | sapreme@trophic.eu